GLP-1 Weight Loss Drugs and Medicare: What's Changing in 2026

GLP-1 medications have changed the conversation around diabetes, weight management, and certain chronic conditions. For Medicare beneficiaries, coverage can depend on the specific drug, the diagnosis, and the rules of the plan.

These medications were originally developed to help manage type 2 diabetes, and some are now also approved for other uses. Common examples include:

• Ozempic, which is used for type 2 diabetes.
• Wegovy, which is approved for chronic weight management and cardiovascular risk reduction.
• Mounjaro, which is used for type 2 diabetes.
• Zepbound, which is approved for chronic weight management and obstructive sleep apnea.

For years, Medicare has generally not covered medications used solely for weight loss. In some cases, coverage may be available when a GLP-1 is prescribed for a covered medical condition rather than for weight loss alone. Even then, approval depends on the plan's formulary, prior authorization rules, and other coverage requirements.

If a plan does cover a GLP-1, the amount you pay can still vary based on the plan tier, pharmacy network, and cost-sharing rules. Some plans may also require step therapy or additional documentation before approving the medication.

The bottom line is that GLP-1 coverage under Medicare is still very plan-specific. If you are comparing Medicare options, it is important to review how each plan handles these medications, because the difference in coverage can have a major impact on your out-of-pocket costs.

If you are looking at Medicare coverage and want to understand how GLP-1 medications may fit into your plan, we can help you review your options.